Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

INDICATION VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). Contraindications Use of VYKAT XR is ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Patients with PWS admitted to the hospital with COVID-19 showed increased risk of in-hospital mortality, severe disease, and mechanical ventilation.

The intense hunger from hyperphagia in Prader-Willi syndrome leads to "food preoccupations ... PWS and their families," Soleno said. The rare genetic neurodevelopmental disorder affects an ...

The Food and Drug Administration on Wednesday approved the first medicine to treat people with Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat. The drug ...

The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, making it the first treatment available for patients who experience feelings of ...

The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder caused by full or partial deletions on chromosome 15 that affect the ...

US FDA Approves First Treatment for Rare Genetic Disorder Prader-Willi Syndrome By Sneha S K (Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to ...